// App-Quantinova.ai

1339 : Targeting Treatment-Naive CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Researchers

Presenter

  • Katharina Rothe

Principal Investigators

  • Matthew V Lorenzi

  • Adrian Woolfson

  • Xiaoyan Jiang

Medical Centers

  • Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada

  • Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Phosphorylated signal transducer and activator of transcription 5

  • Cluster of Differentiation 34

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • Signal transducer and activator of transcription 5

Drug/Treatment

  • Imatinib

  • BMS-911543

  • Nilotinib

  • dasatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved